{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:51Z","timestamp":1777934451746,"version":"3.51.4"},"reference-count":57,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>\n                    Trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), is used to treat breast cancers harboring amplification of the HER2 locus. Cardiotoxicity is a common side effect of trastuzumab that leads to discontinuation of treatment in a significant proportion of cancer patients. In our retrospective study, we evaluate the prevalence and identify the risk factors for cardiotoxicity associated with trastuzumab in HER2-positive breast cancer patients attending to Sultan Qaboos University Hospital between 10\/2012 and 10\/2017. Using patient records, we collected patients\u2019 characteristics (age, menopausal status, lymph nodal status, distant metastasis at presentation, grade of tumor, comorbidities (diabetes mellitus, hypertension, coronary artery disease diseases)), chemotherapy received and total dose of trastuzumab as well as cardiotoxicity (including timing). Cardiotoxicity was defined based on the ejection fraction dropping by 10% of the original value or a drop in the ejection fraction below the normal value. Among the 146 patients included in the study, 35 showed trastuzumab-induced cardiotoxicity (24%). Twenty-nine (83%) of those patients stopped trastuzumab temporarily. Risk of trastuzumab-induced cardiotoxicity was not altered by common cardiac risk factors such as history of coronary artery disease, hypertension and diabetes. Previous anthracyclines therapy exposure increased the risk of trastuzumab-induced cardiotoxicity significantly (\n                    <jats:italic>p\u2009<\/jats:italic>\n                    =\n                    <jats:italic>\u2009<\/jats:italic>\n                    0.009). None of the other covariates influenced the incidence of trastuzumab-induced cardiotoxicity, which may be related to the relatively small sample size. Further studies are warranted to establish ways to predict, prevent, and treat trastuzumab-induced cardiotoxicity to provide patients with maximal therapeutic benefit.\n                  <\/jats:p>","DOI":"10.1177\/1078155220919888","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:12:39Z","timestamp":1588032759000},"page":"312-321","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman"],"prefix":"10.1177","volume":"27","author":[{"given":"Doaa Abd","family":"Alghafar","sequence":"first","affiliation":[{"name":"Pharmacy Department, Sultan Qaboos University Hospital, Seeb, Oman"},{"name":"School of Pharmacy, Queens University, Belfast, Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7792-7459","authenticated-orcid":false,"given":"Ibrahim","family":"Younos","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Medicine, Menoufia University, Shibin Al Kawm, Egypt"},{"name":"Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid Al","family":"Baimani","sequence":"additional","affiliation":[{"name":"Department of Medicine (Oncology Unit), Sultan Qaboos University Hospital, Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawood","family":"Al-Salhi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sultan Qaboos University Hospital, Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Al-Riyami","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology Unit), Sultan Qaboos University Hospital, Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Department of Family Medicine &amp; Public Health, College of Medicine and Health Sciences, Sultan Qaboos University, Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh E","family":"Buckley","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queens University, Belfast, Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"issue":"1","key":"e_1_3_2_2_2","first-page":"S53","article-title":"HER-2\/neu (c-erb-B2) gene and protein in breast cancer","volume":"112","author":"Ross JS","year":"1999","unstructured":"Ross JS, Fletcher JA. HER-2\/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112(1 Suppl 1): S53\u2013S67.","journal-title":"Am J Clin Pathol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B073003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4285"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202132"},{"key":"e_1_3_2_6_2","volume-title":"Therapeutic antibodies. Handbook of experimental pharmacology","author":"Shepard HM","unstructured":"Shepard HM, Jin P, Slamon DJ, et\u00a0al. Herceptin. In: Chernajovsky, Y, Nissim, A (eds) Therapeutic antibodies. Handbook of experimental pharmacology 2008; 181: 183\u2013219."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.737"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0225"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2003.07.007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666040-00005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl475"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-25"},{"key":"e_1_3_2_14_2","first-page":"4744","article-title":"Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina MA","year":"2001","unstructured":"Molina MA, Codony-Servat J, Albanell J, et\u00a0al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744\u20134749.","journal-title":"Cancer Res"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1020"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi059"},{"key":"e_1_3_2_17_2","first-page":"72","article-title":"Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth","author":"Sarup JC","year":"1991","unstructured":"Sarup JC, Johnson RM, King KL, et\u00a0al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991; 72: 82.","journal-title":"Growth Regul"},{"key":"e_1_3_2_18_2","first-page":"4892","article-title":"Downregulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB 2","volume":"61","author":"Cuello M","year":"2001","unstructured":"Cuello M, Ettenberg SA, Clark AS, et\u00a0al. Downregulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB 2. Cancer Res 2001; 61: 4892\u20134900.","journal-title":"Cancer Res"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300848200"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/416279b"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11656"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-459"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_2_24_2","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: a \u2018dual-hit\u2019.","volume":"16","author":"Zeglinski M","year":"2011","unstructured":"Zeglinski M, Ludke A, Jassal DS, et\u00a0al. Trastuzumab-induced cardiac dysfunction: a \u2018dual-hit\u2019. Exp Clin Cardiol 2011; 16: 70\u201374.","journal-title":"Exp Clin Cardiol"},{"key":"e_1_3_2_25_2","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja L","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, et\u00a0al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910383"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1345"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053028"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr348"},{"key":"e_1_3_2_31_2","first-page":"2569","article-title":"Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.","volume":"33","author":"Lemieux J","year":"2013","unstructured":"Lemieux J, Diorio C, C\u00f4t\u00e9 MA, et\u00a0al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013; 33: 2569\u20132576.","journal-title":"Anticancer Res"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5467"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1714-9"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740331003627441"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60840-9"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0125"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2732-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0260-6"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216639755"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0070-y"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.10.015"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9551"},{"key":"e_1_3_2_44_2","first-page":"40","article-title":"A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients.","volume":"107","author":"Matos E","year":"2016","unstructured":"Matos E, Jug B, Blagus R, et\u00a0al. A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. Arq Bras Cardiol 2016; 107: 40\u20137.","journal-title":"Arq Bras Cardiol"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215621150"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4091"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2014.17.4.363"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0463"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.10.001"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9549"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2014.01.001"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005195"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tby003"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0406"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.86.2.219"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.300"},{"key":"e_1_3_2_57_2","first-page":"1","article-title":"safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Darryl PL","year":"2019","unstructured":"Darryl PL, Tammy C, Muhammad MA, et\u00a0al. safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. JACC 2019; 1: 1\u201310.","journal-title":"JACC"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2009.04.011"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220919888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220919888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220919888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:58Z","timestamp":1777688578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220919888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1078155220919888"],"URL":"https:\/\/doi.org\/10.1177\/1078155220919888","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]}}}